{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T10:12:25Z","timestamp":1779358345586,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T00:00:00Z","timestamp":1545091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T00:00:00Z","timestamp":1545091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["200400519A"],"award-info":[{"award-number":["200400519A"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008899","name":"Waksman Foundation of Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008899","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2019,6,1]]},"DOI":"10.1007\/s40256-018-0313-0","type":"journal-article","created":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T07:19:45Z","timestamp":1545117585000},"page":"299-311","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Elderly Japanese Patients with Atherosclerotic Risk Factors: Subanalysis of a Randomized Clinical Trial (JPPP-70)"],"prefix":"10.1007","volume":"19","clinical-trial-number":[{"clinical-trial-number":"nct00225849","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Masahiro","family":"Sugawara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamio","family":"Teramoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Oikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyuki","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuyuki","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Ishizuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuru","family":"Murata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukari","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"On behalf of the Japanese Primary Prevention Project (JPPP) Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamio","family":"Teramoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyuki","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiro","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Oikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiro","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saichi","family":"Hosoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Origasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukito","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayasu","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Minematsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyuki","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Daida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisao","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuru","family":"Murata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,18]]},"reference":[{"key":"313_CR1","unstructured":"World Health Organization. Global status report on noncommunicable diseases. 2014. http:\/\/www.who.int\/nmh\/publications\/ncd-status-report-2014\/en\/. Accessed 26 Sept 2016."},{"key":"313_CR2","unstructured":"World Health Organization. Atlas of heart disease and stroke. 2004. http:\/\/www.who.int\/cardiovascular_diseases\/resources\/atlas\/en\/. Accessed 9 Oct 2016."},{"key":"313_CR3","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1253\/circj.70.1249","volume":"70","author":"Nippon Data Research Group","year":"2006","unstructured":"Nippon Data Research Group. Risk assessment chart for death from cardiovascular disease based on a 19-year follow-up study of a Japanese representative population. Circ J. 2006;70:1249\u201355.","journal-title":"Circ J"},{"key":"313_CR4","unstructured":"Ministry of Health Labour and Welfare Japan. Ministry of Health, Labour and Welfare Report: 2014. [Japanese]. http:\/\/www.mhlw.go.jp\/wp\/hakusyo\/kousei\/14\/. Accessed 6 Oct 2016."},{"key":"313_CR5","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1161\/CIRCULATIONAHA.113.002424","volume":"128","author":"J Hata","year":"2013","unstructured":"Hata J, Ninomiya T, Hirakawa Y, et al. Secular trends in cardiovascular disease and its risk factors in Japanese: half-century data from the Hisayama Study (1961\u20132009). Circulation. 2013;128:1198\u2013205.","journal-title":"Circulation"},{"key":"313_CR6","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12959-015-0068-7","volume":"13","author":"JR Nansseu","year":"2015","unstructured":"Nansseu JR, Noubiap JJ. Aspirin for primary prevention of cardiovascular disease. Thromb J. 2015;13:38.","journal-title":"Thromb J."},{"key":"313_CR7","doi-asserted-by":"crossref","unstructured":"Antithrombotic Trialists\u2019 (ATT) Collaboration, Baigent C, Blackwell L, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849\u201360.","DOI":"10.1016\/S0140-6736(09)60503-1"},{"key":"313_CR8","doi-asserted-by":"publisher","first-page":"e0160046","DOI":"10.1371\/journal.pone.0160046","volume":"11","author":"LA Garcia Rodriguez","year":"2016","unstructured":"Garcia Rodriguez LA, Martin-Perez M, Hennekens CH, Rothwell PM, Lanas A. Bleeding risk with long-term low-dose aspirin: a systematic review of observational studies. PLoS One. 2016;11:e0160046.","journal-title":"PLoS One"},{"key":"313_CR9","doi-asserted-by":"crossref","unstructured":"Bibbins-Domingo K, Force USPST. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2016;164:836\u201345.","DOI":"10.7326\/M16-0577"},{"key":"313_CR10","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1001\/jama.2014.15690","volume":"312","author":"Y Ikeda","year":"2014","unstructured":"Ikeda Y, Shimada K, Teramoto T, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60\u00a0years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA. 2014;312:2510\u201320.","journal-title":"JAMA"},{"key":"313_CR11","doi-asserted-by":"crossref","unstructured":"Ogawa H, Nakayama M, Morimoto T, Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) trial, et al. Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300:2134\u201341.","DOI":"10.1001\/jama.2008.623"},{"key":"313_CR12","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1161\/CIRCULATIONAHA.116.025760","volume":"135","author":"Y Saito","year":"2017","unstructured":"Saito Y, Okada S, Ogawa H, et al. Low-dose aspirin for primary prevention of cardiovascular events in patients with type 2 diabetes mellitus: 10-year follow-up of a randomized controlled trial. Circulation. 2017;135:659\u201370.","journal-title":"Circulation"},{"issue":"361\u20139","key":"313_CR13","first-page":"e364","volume":"159","author":"T Teramoto","year":"2010","unstructured":"Teramoto T, Shimada K, Uchiyama S, et al. Rationale, design, and baseline data of the Japanese Primary Prevention Project (JPPP)-a randomized, open-label, controlled trial of aspirin versus no aspirin in patients with multiple risk factors for vascular events. Am Heart J. 2010;159(361\u20139):e364.","journal-title":"Am Heart J"},{"key":"313_CR14","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1291\/hypres.29.S1","volume":"29","author":"Japanese Society of Hypertension","year":"2006","unstructured":"Japanese Society of Hypertension. Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2004). Hypertens Res. 2006;29:S1\u2013105.","journal-title":"Hypertens Res"},{"key":"313_CR15","unstructured":"Japan Atherosclerosis Society. Japan Atherosclerosis Society (JAS) guidelines for diagnosis and treatment of atherosclerotic cardiovascular diseases. 2002. http:\/\/www.researchgate.net\/publication\/246586151_1FS03-4_Japan_atherosclerosis_society_(JAS)_guidelines_for_diagnosis_and_treatment_of_atherosclerotic_cardiovascular_diseases. Accessed 9 Oct 2016."},{"key":"313_CR16","volume-title":"Evidence-based practice guideline for the treatment of diabetes in Japan [in Japanese]","author":"The Japan Diabetes Society","year":"2004","unstructured":"The Japan Diabetes Society. Evidence-based practice guideline for the treatment of diabetes in Japan [in Japanese]. Tokyo: Nankodo; 2004."},{"key":"313_CR17","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1161\/CIR.0b013e3182009701","volume":"123","author":"VL Roger","year":"2011","unstructured":"Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics\u20132011 update: a report from the American Heart Association. Circulation. 2011;123:e18\u2013209.","journal-title":"Circulation"},{"key":"313_CR18","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1161\/STROKEAHA.115.012461","volume":"47","author":"S Uchiyama","year":"2016","unstructured":"Uchiyama S, Ishizuka N, Shimada K, et al. Aspirin for stroke prevention in elderly patients with vascular risk factors: Japanese Primary Prevention Project. Stroke. 2016;47:1605\u201311.","journal-title":"Stroke"},{"key":"313_CR19","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1212\/WNL.0b013e31829e6ffa","volume":"81","author":"LA Garcia-Rodriguez","year":"2013","unstructured":"Garcia-Rodriguez LA, Gaist D, Morton J, Cookson C, Gonzalez-Perez A. Antithrombotic drugs and risk of hemorrhagic stroke in the general population. Neurology. 2013;81:566\u201374.","journal-title":"Neurology."},{"key":"313_CR20","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s40256-014-0100-5","volume":"15","author":"C Brotons","year":"2015","unstructured":"Brotons C, Benamouzig R, Filipiak KJ, Limmroth V, Borghi C. A systematic review of aspirin in primary prevention: is it time for a new approach? Am J Cardiovasc Drugs. 2015;15:113\u201333.","journal-title":"Am J Cardiovasc Drugs."},{"key":"313_CR21","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/pds.3391","volume":"22","author":"D Gaist","year":"2013","unstructured":"Gaist D, Wallander MA, Gonzalez-Perez A, Garcia-Rodriguez LA. Incidence of hemorrhagic stroke in the general population: validation of data from the Health Improvement Network. Pharmacoepidemiol Drug Saf. 2013;22:176\u201382.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"313_CR22","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1016\/S0195-668X(03)00485-8","volume":"24","author":"M Moscucci","year":"2003","unstructured":"Moscucci M, Fox KA, Cannon CP, et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J. 2003;24:1815\u201323.","journal-title":"Eur Heart J"},{"key":"313_CR23","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ahj.2012.05.008","volume":"164","author":"MD Miedema","year":"2012","unstructured":"Miedema MD, Cohn JN, Garberich RF, Knickelbine T, Graham KJ, Henry TD. Underuse of cardiovascular preventive pharmacotherapy in patients presenting with ST-elevation myocardial infarction. Am Heart J. 2012;164:259\u201367.","journal-title":"Am Heart J"},{"key":"313_CR24","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1001\/archinternmed.2011.628","volume":"172","author":"SR Seshasai","year":"2012","unstructured":"Seshasai SR, Wijesuriya S, Sivakumaran R, et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med. 2012;172:209\u201316.","journal-title":"Arch Intern Med"},{"key":"313_CR25","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1161\/CIRCOUTCOMES.113.000690","volume":"7","author":"MD Miedema","year":"2014","unstructured":"Miedema MD, Duprez DA, Misialek JR, et al. Use of coronary artery calcium testing to guide aspirin utilization for primary prevention: estimates from the multi-ethnic study of atherosclerosis. Circ Cardiovasc Qual Outcomes. 2014;7:453\u201360.","journal-title":"Circ Cardiovasc Qual Outcomes."},{"key":"313_CR26","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1016\/j.amjcard.2011.02.325","volume":"107","author":"AA Bartolucci","year":"2011","unstructured":"Bartolucci AA, Tendera M, Howard G. Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin. Am J Cardiol. 2011;107:1796\u2013801.","journal-title":"Am J Cardiol"},{"key":"313_CR27","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.amjmed.2011.01.018","volume":"124","author":"N Raju","year":"2011","unstructured":"Raju N, Sobieraj-Teague M, Hirsh J, O\u2019Donnell M, Eikelboom J. Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Am J Med. 2011;124:621\u20139.","journal-title":"Am J Med"},{"key":"313_CR28","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1161\/CIR.0000000000000230","volume":"132","author":"CS Fox","year":"2015","unstructured":"Fox CS, Golden SH, Anderson C, et al. Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2015;132:691\u2013718.","journal-title":"Circulation"},{"key":"313_CR29","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.1161\/STR.0000000000000046","volume":"45","author":"JF Meschia","year":"2014","unstructured":"Meschia JF, Bushnell C, Boden-Albala B, et al. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke. 2014;45:3754\u2013832.","journal-title":"Stroke"},{"key":"313_CR30","unstructured":"British Hypertension Society. The use of aspirin in primary prevention of cardiovascular disease. 2010. http:\/\/www.bhsoc.org\/pdfs\/Statement%20on%20Aspirin%20Jan10.pdf. Accessed 28 Sept 2016."},{"key":"313_CR31","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1001\/jamainternmed.2016.2648","volume":"176","author":"S Mora","year":"2016","unstructured":"Mora S, Manson JE. Aspirin for primary prevention of atherosclerotic cardiovascular disease: advances in diagnosis and treatment. JAMA Intern Med. 2016;176:1195\u2013204.","journal-title":"JAMA Intern Med."},{"key":"313_CR32","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1805819","volume":"379","author":"JJ McNeil","year":"2018","unstructured":"McNeil JJ, Wolfe R, Woods RL, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med. 2018;379:1509\u201318.","journal-title":"N Engl J Med."},{"key":"313_CR33","doi-asserted-by":"crossref","unstructured":"Li L, Geraghty OC, Mehta Z, Rothwell PM, Oxford Vascular Study. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet. 2017;390:490\u201399.","DOI":"10.1016\/S0140-6736(17)30770-5"},{"key":"313_CR34","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","volume":"379","author":"The ASCEND Study Collaborative Group","year":"2018","unstructured":"The ASCEND Study Collaborative Group. Effect of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379:1529\u201339.","journal-title":"N Engl J Med."},{"key":"313_CR35","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/S0140-6736(18)31924-X","volume":"392","author":"JM Gaziano","year":"2018","unstructured":"Gaziano JM, Brotons C, Coppolecchia R, et al. Use of aspirin to reduce risk of initial vascular events in patient at moderate risk of cardiovascular disease (ARRIVE): a randomized, double-blind, placebo-controlled trial. Lancet. 2018;392:1036\u201346.","journal-title":"Lancet"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-018-0313-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-018-0313-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-018-0313-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T17:37:21Z","timestamp":1628617041000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-018-0313-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,18]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6,1]]}},"alternative-id":["313"],"URL":"https:\/\/doi.org\/10.1007\/s40256-018-0313-0","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,18]]},"assertion":[{"value":"18 December 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"TY reports receiving personal fees from AstraZeneca, Dainippon Sumitomo, Shionogi, and Takeda. TT reports receiving grant support from Daiichi Sankyo, Eli Lilly, Kowa, Shionogi, and Takeda; speaker fees from Amgen Astellas BioPharma, Astellas, Bayer, Daiichi Sankyo, Kissei, Kowa, Pfizer, Sanofi, and Takeda; and department endowments from Aska, Astellas, Bayer, Kissei, Kowa, and MSD. SO reports receiving personal fees from Astellas, Bayer, Daiichi Sankyo, Kyowa Hakko Kirin, Mochida, MSD, and Takeda. SU reports receiving speaker fees from AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Dainihon Sumitomo, Otsuka, Shionogi, Takeda, and Tanabe Mitsubishi. KA reports receiving speaker fees from Bayer, Daiichi Sankyo, Mochida, MSD, and Torii Pharmaceutical. NI reports being a former employee of Sanofi-Aventis. MM reports receiving grant support from Bayer, Daiichi Sanko, Pfizer, Sanofi-Aventis, and Taisho-Toyama, and personal fees from Dainihon-Sumitomo, Otsuka, and Taisho-Toyama. KY reports grants from Nippon Shinyaku, Bristol-Myers Squibb, Chugai, Takeda, Pfizer, Kyowa Hakko Kirin, and Eisai, and personal fees from Nippon Shinyaku, Celgene Japan, Bayer, Bristol-Myers Squibb, Novartis, Takeda, Pfizer, Kyowa Hakko Kirin, and Otsuka. YU reports receiving grants from the JPPP study secretariat. YI reports receiving fees for medical advice from AstraZeneca, Bayer, Daiichi Sankyo, GlaxoSmithKline, and Sanofi-Aventis. MS, YG, and KS declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The JPPP was sponsored by the Japanese Ministry of Health, Labour, and Welfare (Grant Number 200400519A) and the Waksman Foundation of Japan. The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Enteric-coated 100-mg aspirin tablets were provided free of charge by Bayer Yakuhin, Japan.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}